DCOYDecoy Therapeutics Inc.
$6.61
$0.10
(1.49%)
Closed $6.61
$0.45
(6.81%)
After Hours
Mkt Cap$3.57M
Vol22,084.00
Fundamentals
Mkt Cap
$3.57M
Volume
-
52W High
$415.80
52W Low
$4.32
PE Ratio
-0.05
Avg. Volume
11,444.42
EPS (Annual)
-$129.10
Rev/Employee
$0.00
Earnings
-
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors PR Newswire CAMBRIDGE, Mass., June 3, 2026 CAMBRIDGE, Mass., June 3, 2026...
PR Newswire
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic PR Newswire CAMBRIDGE, Mass., June 1, 2026 Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new...
PR Newswire
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board PR Newswire NEW YORK and CAMBRIDGE, Mass., May 26, 2026 Appointment deepens...
PR Newswire
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston PR Newswire CAMBRIDGE, Mass., April 27...
PR Newswire
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline Decoy Therapeutics...
PR Newswire
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 Live video webcast...
PR Newswire
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ --Decoy Therapeutics, Inc...
PR Newswire
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform Decoy Therapeutics Enters Strategic...
PR Newswire
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split Decoy Therapeutics Announces 1-for-12 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., March 5, 2026 CAMBRIDGE, Mass., March 5, 2026...
PR Newswire
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Decoy Therapeutics Joins Webull Corporate Connect Service Platform Decoy Therapeutics Joins Webull Corporate Connect Service Platform PR Newswire CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 - Connect...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest DCOY News
ViewDecoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
PR Newswire
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic
PR Newswire
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
PR Newswire
Advertisement|Remove ads.